- Home
- PVLA vs ABEO Comparison
PVLA vs ABEO Comparison
Compare PVLA & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PVLA
- ABEO
- Stock Information
- Founded
- PVLA 2015
- ABEO 1974
- Country
- PVLA United States
- ABEO United States
- Employees
- PVLA N/A
- ABEO N/A
- Industry
- PVLA Biotechnology: Pharmaceutical Preparations
- ABEO Biotechnology: Pharmaceutical Preparations
- Sector
- PVLA Health Care
- ABEO Health Care
- Exchange
- PVLA Nasdaq
- ABEO Nasdaq
- Market Cap
- PVLA 285.2M
- ABEO 304.4M
- IPO Year
- PVLA N/A
- ABEO 1980
- Fundamental
- Price
- PVLA $36.55
- ABEO $6.49
- Analyst Decision
- PVLA Strong Buy
- ABEO Strong Buy
- Analyst Count
- PVLA 8
- ABEO 6
- Target Price
- PVLA $47.50
- ABEO $18.00
- AVG Volume (30 Days)
- PVLA 176.0K
- ABEO 673.1K
- Earning Date
- PVLA 08-15-2025
- ABEO 08-11-2025
- Dividend Yield
- PVLA N/A
- ABEO N/A
- EPS Growth
- PVLA N/A
- ABEO N/A
- EPS
- PVLA N/A
- ABEO N/A
- Revenue
- PVLA N/A
- ABEO N/A
- Revenue This Year
- PVLA N/A
- ABEO N/A
- Revenue Next Year
- PVLA N/A
- ABEO $322.37
- P/E Ratio
- PVLA N/A
- ABEO N/A
- Revenue Growth
- PVLA N/A
- ABEO N/A
- 52 Week Low
- PVLA $11.17
- ABEO $3.93
- 52 Week High
- PVLA $40.50
- ABEO $7.32
- Technical
- Relative Strength Index (RSI)
- PVLA N/A
- ABEO 54.10
- Support Level
- PVLA N/A
- ABEO $6.36
- Resistance Level
- PVLA N/A
- ABEO $6.94
- Average True Range (ATR)
- PVLA 0.00
- ABEO 0.33
- MACD
- PVLA 0.00
- ABEO 0.00
- Stochastic Oscillator
- PVLA 0.00
- ABEO 52.99
About PVLA Palvella Therapeutics Inc. Common Stock
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.